{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:22:46Z","timestamp":1795026166765,"version":"4.10.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23725","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T16:08:29Z","timestamp":1702656509000},"page":"e23725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-9445","authenticated-orcid":false,"given":"Riccardo","family":"Giossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e23725_bib1","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.heliyon.2023.e23725_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.13251","article-title":"Pathophysiology of severe asthma: we\u2019ve only just started","volume":"23","author":"King","year":"2018","journal-title":"Respirology. Australia"},{"key":"10.1016\/j.heliyon.2023.e23725_bib3","first-page":"814","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/clinids\/18.4.627","article-title":"Disseminated coccidioidomycosis associated with extreme eosinophilia","volume":"18","author":"Harley","year":"1994","journal-title":"Clin Infect Dis an Off Publ Infect Dis Soc Am. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaci.2015.04.041","article-title":"Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes","volume":"137","author":"Ueki","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23725_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood-2013-05-502443","article-title":"Activated mouse eosinophils protect against lethal respiratory virus infection","volume":"123","author":"Percopo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e23725_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2020.04.021","article-title":"Eosinophil responses during COVID-19 infections and coronavirus vaccination","volume":"146","author":"Lindsley","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23725_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.668074","article-title":"Eosinophils and chronic respiratory diseases in hospitalized COVID-19 patients","volume":"12","author":"Valverde-Monge","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23725_bib10","first-page":"10","article-title":"Eosinopenia as a marker of outcome in acute exacerbations of chronic obstructive pulmonary disease","volume":"10","author":"Rahimi-Rad","year":"2015","journal-title":"Maedica (Buchar)"},{"key":"10.1016\/j.heliyon.2023.e23725_bib11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12879-021-06150-3","article-title":"Silent existence of eosinopenia in sepsis: a systematic review and meta-analysis","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.heliyon.2023.e23725_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/all.14514","article-title":"Asthma exacerbations on benralizumab are largely non-eosinophilic","author":"Poznanski","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.heliyon.2023.e23725_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23725_bib14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000444799","article-title":"A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan","volume":"169","author":"Park","year":"2016","journal-title":"Int Arch Allergy Immunol. Switzerland"},{"key":"10.1016\/j.heliyon.2023.e23725_bib16","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2023.e23725_bib17","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2023.e23725_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir Med. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib19","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JAA.S172338","article-title":"Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial","volume":"11","author":"Zeitlin","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.heliyon.2023.e23725_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JAA.S240044","article-title":"Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase IIIb randomized, controlled trial (SOLANA)","volume":"13","author":"Panettieri","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.heliyon.2023.e23725_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e23725_bib25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2023.e23725_bib26","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib31","first-page":"789","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib32","first-page":"799","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","article-title":"Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo","volume":"8","author":"Bernstein","year":"2020","journal-title":"Lancet Respir Med. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib34","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin Exp allergy J Br Soc Allergy Clin Immunol. England"},{"key":"10.1016\/j.heliyon.2023.e23725_bib35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/19458924211009429","article-title":"A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am J Rhinol Allergy. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol. United States"},{"key":"10.1016\/j.heliyon.2023.e23725_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102913","article-title":"Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma","volume":"24","author":"Hassani","year":"2021","journal-title":"iScience"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023109339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023109339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:20:40Z","timestamp":1790655640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023109339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023109339"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23725","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23725"}}